Detecting early syphilis using unique bacterial fragments
Released peptidoglycan fragments are a biomarker for early stages of syphilis
This study is looking at a new way to quickly and accurately detect syphilis by using tiny pieces of the bacteria that cause it, which could help people get treated faster than with current tests.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-11196339 on NIH RePORTER |
What this research studies
This research investigates the potential of using fragments of the bacterial cell wall from Treponema pallidum, the bacterium that causes syphilis, as a biomarker for early detection of the infection. By developing a new diagnostic test that identifies these unique peptidoglycan fragments, the goal is to provide quicker and more accurate results than current serological tests, which can take weeks to show a response. The study utilizes advanced culture methods to propagate the bacteria and analyze the fragments shed during its growth, aiming to improve patient outcomes through timely treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who may have been recently exposed to syphilis or are showing early symptoms of the infection.
Not a fit: Patients who have been diagnosed with syphilis for an extended period or those who are not at risk of exposure may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to faster and more accurate diagnosis of syphilis, allowing for immediate treatment and better health outcomes.
How similar studies have performed: While the approach of using peptidoglycan fragments as biomarkers is innovative, similar research has shown promise in other bacterial infections, suggesting potential for success in this area as well.
Where this research is happening
Chicago, United States
- Northwestern University at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Jutras, Brandon Lyon — Northwestern University at Chicago
- Study coordinator: Jutras, Brandon Lyon
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.